Nevro (NVRO) to Release Earnings on Tuesday

Nevro (NYSE:NVRO) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Nevro to post earnings of ($1.02) per share for the quarter. Nevro has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Wednesday, February 21st. The medical equipment provider reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.35. Nevro had a negative return on equity of 30.22% and a negative net margin of 21.69%. The firm had revenue of $116.18 million for the quarter, compared to analysts’ expectations of $115.93 million. On average, analysts expect Nevro to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nevro Stock Up 1.3 %

NYSE:NVRO opened at $11.29 on Monday. The company has a quick ratio of 4.94, a current ratio of 6.37 and a debt-to-equity ratio of 0.72. The stock’s fifty day moving average is $13.37 and its two-hundred day moving average is $16.34. Nevro has a 52 week low of $10.27 and a 52 week high of $28.89. The stock has a market capitalization of $414.12 million, a price-to-earnings ratio of -4.39 and a beta of 0.96.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NVRO shares. StockNews.com upgraded Nevro from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Robert W. Baird decreased their price target on Nevro from $23.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, February 22nd. Royal Bank of Canada decreased their price target on Nevro from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Monday, April 15th. Citigroup decreased their price target on Nevro from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 3rd. Finally, Mizuho cut their price objective on Nevro from $20.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, April 11th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Nevro currently has an average rating of “Hold” and a consensus target price of $21.23.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.